RSLS Earnings
ReShape Lifesciences Inc
$
2.030
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of ReShape Lifesciences Inc(RSLS) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of ReShape Lifesciences Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| - | 2025-08-13 | After Hours | - | - | - | - | - | - | - | - |
| - | 2024-08-14 | After Hours | - | -0.06 | - | - | 1.97M | - | -1.12 | -5.62 |
| - | 2024-08-05 | - | - | -1.08 | - | - | - | - | -6.04 | -2.20 |
| FY2024Q1 | 2024-05-15 | - | - | -0.09 | - | 2.10M | 1.94M | -7.60 | +4.82 | +11.45 |
RSLS Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, ReShape Lifesciences Inc reported performance for , announced on 2025-08-13. The company achieved an EPS of , compared to analyst estimates of by % . Revenue for the quarter reached 0.00 compared to expectations of 0.00 by % .
The stock price reacted with a % one-day change and a % five-day change following the earnings release. These movements reflect market reaction in ReShape Lifesciences Inc growth trajectory and strategic initiatives.
RSLS Earnings Forecast
Looking ahead, ReShape Lifesciences Inc(RSLS) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for have been Go Down by -67.52%, while EPS estimates have been No Change by %. For the upcoming , revenue estimates have been adjusted No Change by % . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in ReShape Lifesciences Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between RSLS's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Stock Price
Go Down
-67.52%
In Past 3 Month
1Y
3Y
5Y
Fiscal Period
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price2.03
RSLS Revenue and EPS Performance: A Historical Perspective
ReShape Lifesciences Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
(2025-08-13,After Hours):
EPS: (Actual) vs. (Estimate) (%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: %(1-Day), %(5-Day)
(2024-08-14,After Hours):
EPS: -0.06 (Actual) vs. (Estimate) (%)
Revenue: 1.97M (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: -1.12%(1-Day), -5.62%(5-Day)
(2024-08-05,):
EPS: -1.08 (Actual) vs. (Estimate) (%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: -6.04%(1-Day), -2.20%(5-Day)
Earnings Reaction
The chart below shows how RSLS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RSLS sees a +8.62% change in stock price 10 days leading up to the earnings, and a +9.24% change 10 days following the report. On the earnings day itself, the stock moves by +0.29%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2024, the stock changed -1.01% on the day following the earnings release and then changed by -12.93% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Summary
Neutral
2024-11-15
The earnings call highlights a mix of positive and negative factors. The merger and asset purchase agreements are strategic moves that could enhance shareholder value, but there are risks associated with integration and market adoption challenges. Financial performance shows modest revenue growth and improved margins, but overall sales have contracted. The Q&A session reveals uncertainties about product development and market competition from GLP-1s. Despite cost reductions, the lack of strong guidance and the uncertainty in market adoption balance the positives, suggesting a neutral sentiment with limited short-term stock price movement.
ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Summary
Negative
2024-08-16
The earnings call highlights a revenue decline due to competitive pressures, supply chain challenges, and regulatory risks, despite cost reductions. The merger and asset sales could enhance future growth, but immediate concerns overshadow these prospects. The Q&A lacks clarity, further adding uncertainty. Overall, the negative financial performance and risks outweigh the positive elements, leading to a likely negative stock price movement.
People Also Watch
PTIX
Protagenic Therapeutics Inc
2.750
USD
-1.79%
TNFA
TNF Pharmaceuticals Inc
0.110
USD
0.00%
AZTR
Azitra Inc
0.147
USD
-7.54%
SHPH
Shuttle Pharmaceuticals Holdings Inc
3.590
USD
+4.36%
TC
Token Cat Ltd
0.710
USD
-2.74%
AQB
AquaBounty Technologies Inc
0.740
USD
-1.99%
KTTA
Pasithea Therapeutics Corp
0.700
USD
+3.10%
YCBD
cbdMD Inc
0.944
USD
-2.78%
FAMI
Farmmi Inc
1.590
USD
-0.63%
CNET
ZW Data Action Technologies Inc
1.340
USD
+0.60%
FAQ
What were the key highlights of RSLS’s latest earnings report for ?
RSLS reported its earnings on 2025-08-13, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.
How did RSLS’s stock price react after the earnings release?
What are the revenue and EPS estimates for RSLS for undefined?
How does RSLS’s stock price correlate with earnings forecast revisions?
What should investors expect from RSLS’s next earnings report?